Demonstrating efficacy is challenging with CNS therapeutics.
Phase 1 to FDA approval
as likely as other therapeutic areas
as likely to fail in phase 3
CNS diseases are often complex, poorly defined, and difficult to measure. Also, patients are known to exhibit highly differential responses to CNS therapeutics, highlighting the need for patient measurement and stratification.
Objective and automated measurement using multimodal AI enhances signal detection.
Deliberate helps clinical trial sponsors achieve enhanced endpoint reliability, reduced sample size, faster completion, and lower cost.
Our platform captures and analyzes signs beyond what a human clinician can perceive, including accurate side effect quantification.
Precision enrollment & enrichment.
With Deliberate, sponsors can screen and verify patients, capture validated baseline measures, and even perform patient enrichment via a companion Dx.
How we do it.
Our multimodal AI platform analyzes biomarker constellations™ to objectively measure disease signs across CNS indications
Distinguished Poster Award
18th Annual Scientific Meeting, 2022